Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review: 2型糖尿病患者中发生癌症风险与磺脲类药物使用相关性的系统性评价
Abstract
Background Increasing evidence suggests that oral hypoglycemic agents used in type 2 diabetes mellitus (T2DM) may affect cancer risk. Sulfonylureas (SUs) are the most frequently used antidiabetic medications for T2DM. Whether using SUs has any effect on cancer has received considerable attention. The aim of this study was to assess the effects of SUs on cancer risk in T2DM patients. Methods Published studies were identified in PubMed, EMBASE, and the Cochrane Register of Clinical Studies, and ClinicalTrials.gov was searched for additional information to identify randomized controlled trials (RCTs), cohort studies, and case-control studies. The abstracts and full text were screened, data collected, and the risk of bias assessed for each individual study. Results Seventy-seven studies (33 RCTs, 27 cohort studies, and 17 case-control studies) were analyzed. The RCTs did not report a difference in the risk of malignant tumor between SU-treated T2DM patients and controls (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.78-1.18); cohort studies showed that cancer risk was higher in patients using SUs than metformin (relative risk 1.60 [95%CI 1.37-1.87]; adjusted hazard ratio 1.13 [95%CI 1.06-1.19]), and case-control studies suggested a trend for increased cancer risk in those using SUs compared with non-SU users (adjusted OR 1.13; 95%CI 0.93-1.37). Conclusions The available evidence clearly shows that SUs can significantly increase the risk of cancer compared with metformin. A…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Modest survival benefits with metformin have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1798]
Cites
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284 · see citing works
Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3042 · Cited by 203 · see citing works
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Mamtani, R., Pfanzelter, N., Haynes, K., Finkelman, B. S., Wang, X., Keefe, S. M., Haas, N. B., Vaughn, D. J., & Lewis, J. D. (2014) · Diabetes Care · doi:10.2337/dc13-1489 · Cited by 71 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
- Authors
- Chen, Y., Du, L., Li, L., Ma, J., Geng, X., Yao, X., Liu, G., & Sun, X.
- Affiliations
- Sichuan University (CN)
- The Second People's Hospital Mudanjiang China
- Hubei University of Medicine (CN)
- Corresponding author
- Sun, Xin
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2016-09-09
- Volume
- 9
- Issue
- 5
- Pages
- 482-494
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2417046068
- Cited by
- 37
- References
- 3
- Citations by year
- 2026: 4 · 2024: 6 · 2023: 1 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 6 · 2017: 2
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sichuan University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- sulfonylureas, type 2 diabetes, cancer risk, oral antidiabetic drugs, metformin, drug safety, antidiabetic drugs
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Risk Factors, Sulfonylurea Compounds, Cohort Studies, Case-Control Studies, Randomized Controlled Trials as Topic, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
